SINTX preliminary Q3 revenue totals about $2.2M
$2.1 million in qualifying revenue meets the Class B warrant call threshold, but exercise proceeds are not assured.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
SINTX Technologies, Inc. reported preliminary, unaudited revenue of approximately $2.2 million for the quarter ended September 30, 2026, including approximately $2.1 million from product sales. The figures remain subject to quarter-end close and review. Revenue was roughly 380% higher than Q2 and more than ten times the prior-year quarter, exceeding prior guidance of $0.9 million to $1.1 million. SINTX reiterated its fourth-quarter 2026 revenue guidance.
SINTX intends to deliver a Call Notice to holders of Class B Warrants, after determining that approximately $2.1 million qualifies as Quarterly Revenue against a trigger of at least $2.0 million. The warrants are to purchase approximately 1.88 million common shares. If fully exercised under their terms, they could provide up to $4.0 million in cash proceeds; exercise proceeds are not assured.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Positive
- Moderate pointQ3 revenue increased roughly 380% from Q2.
Negative
- None.
Filing Explained
The per-share exercise price will be the common stock’s closing price on the trading day before the Call Notice, and warrants not exercised on time automatically expire; therefore, the potential proceeds of up to
8-K Event Classification
Key Figures
Key Terms
Quarterly Revenue financial
Revenue Evidence Filing financial
Call Notice financial
quarter-end financial close and review procedures financial
Earnings Snapshot
SINTX reiterated its fourth-quarter 2026 revenue guidance.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
How much revenue did SINT report for Q3 2026?
What are the SINT Class B warrant call terms?
How is the SINT warrant exercise price set, and what happens if holders do not exercise?
AI-generated analysis. How Rhea-AI works. Not financial advice.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
(State or other jurisdiction of incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
(Address of principal executive offices, including Zip Code)
Registrant’s
telephone number, including area code:
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class: | Trading Symbol(s): | Name of each exchange on which registered: | ||
| The
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging
growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition.
On October 1, 2026, SINTX Technologies, Inc. (the “Company”) issued a press release announcing preliminary, unaudited revenue for the fiscal quarter ended September 30, 2026 and providing an update regarding the Company’s previously announced revenue guidance. The Company reported preliminary, unaudited revenue of approximately $2.2 million for the quarter ended September 30, 2026, of which approximately $2.1 million was derived from product sales.
The preliminary financial information described above is based on information currently available to management and remains subject to completion of the Company’s quarter-end financial close and review procedures.
A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
Item 7.01. Regulation FD Disclosure.
As described in the press release furnished as Exhibit 99.1, based on the preliminary quarterly revenue described under Item 2.02 above, the Company intends to deliver a Call Notice to the holders of its outstanding Class B Common Stock Purchase Warrants (the “Class B Warrants”) pursuant to the terms of the Class B Warrants.
The Class B Warrants provide the Company with the right to call for exercise all or a portion of the outstanding Class B Warrants upon the Company reporting Quarterly Revenue, as defined in the Class B Warrants, of at least $2.0 million for a fiscal quarter in a qualifying Revenue Evidence Filing. The Company has determined that approximately $2.1 million of its revenue for the quarter ended September 30, 2026 constitutes Quarterly Revenue for purposes of the Class B Warrants.
The press release also includes information regarding the Company’s fourth-quarter 2026 revenue outlook and certain business and operational developments.
The information furnished pursuant to Items 2.02 and 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits.
| Exhibit No. | Description | |
| 99.1 | Press Release dated October 1, 2026 | |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| SINTX Technologies, Inc. | ||||
| Date: | October 1, 2026 | By: | /s/ Eric K. Olson | |
| Eric K. Olson | ||||
| Chief Executive Officer | ||||
Exhibit 99.1
SINTX Announces Preliminary $2.2 Million in Q3 Revenue, Exceeding High-End Guidance
Third-quarter revenue grows roughly 380% from Q2, driven by stronger-than-expected industrial sales to Fortune 500 customers; Company reiterates Q4 revenue guidance
Revenue milestone also enables Company to call Class B warrants
SALT LAKE CITY, Utah – October 1, 2026 – SINTX Technologies, Inc. (NASDAQ: SINT) (“SINTX” or the “Company”), a leader in advanced silicon nitride biomaterials and ceramics for medical and industrial applications, today announced preliminary, unaudited revenue of $2.2 million* for the third quarter ended September 30, 2026. The result exceeds the high end of the Company’s previously announced guidance of $0.9 million to $1.1 million, reflecting stronger-than-expected industrial ceramics sales, and is expected to result in narrower losses than previous quarters.
Sales of industrial parts to aerospace subsidiaries of Fortune 500 companies accounted for the majority of third-quarter revenue. During the quarter, SINTX began shipments against the more than $3.2 million in contract manufacturing purchase orders announced in June, converting a portion of those orders into recognized revenue. The Company reiterates its fourth-quarter revenue guidance range offered during its last quarterly earnings call.
“We are pleased by the results of our efforts to improve manufacturing and operational efficiency in the third quarter,” said Eric Olson, Chairman and CEO of SINTX. “In addition to the significantly narrowed losses we expect to see as a result of these sales and nearly doubling the high end of the guidance we provided in August, our 2026 third-quarter revenue represents growth of roughly 380% from the second quarter, and over ten times the revenue from the prior year quarter.”
During 2026, SINTX has expanded the commercial infrastructure supporting its silicon nitride orthopedic portfolio, including its FDA-cleared SiNAPTIC® Foot & Ankle Osteotomy Wedge System. SINTX continues to develop its silicon nitride SiNERGY™ technology platform across biocomposite and 3D printing capabilities, as well as its antimicrobial textiles as part of the overall platform for orthopedic, spine, craniofacial, dental, suture and wound-management applications.
Mr. Olson continued, “This quarter demonstrates our ability to turn industrial customer orders into revenue at scale through our U.S. manufacturing operations. Our focus now is on reliable delivery, repeat business and disciplined manufacturing costs. We see this execution as an important foundation for SINTX as we continue our transition towards a more diversified commercial-stage advanced materials company.”
Concurrent with issuing this press release on Form 8-K, the Company also intends to deliver a Call Notice to the holders of Class B Warrants to purchase an aggregate of approximately 1.88 million shares of the Company’s Common Stock. Roughly $2.1 million of the third-quarter revenue was derived from product sales, surpassing the Call Right trigger of at least $2.0 million in product revenue during a fiscal quarter. Per the terms of the Warrant, the per share exercise price shall be the closing price of the Company’s Common Stock at the close of the trading day immediately preceding the date of the Call Notice; if fully exercised under the terms of the Warrant, cash proceeds could provide up to $4.0 million in additional capital, while any Warrants or portion of Warrants that the Holders fail to exercise in a timely manner will automatically expire. Exercise proceeds are not assured.
*This amount represents preliminary recognized revenue for the quarter, while the Company is completing its quarter-end financial close and review procedures. The preliminary revenue figure is based on information currently available to management, is unaudited, and remains subject to adjustment. SINTX expects to provide complete third-quarter financial results in its forthcoming quarterly reporting. Final reported revenue could differ materially.
About SINTX Technologies, Inc.
Headquartered in Salt Lake City, Utah, SINTX Technologies, Inc. (NASDAQ: SINT) is an advanced ceramics and biomaterials company that develops, manufactures, and commercializes silicon nitride biomaterials, composites, devices, and related technologies for medical and other high-value applications. SINTX’s technologies are supported by peer-reviewed research, a patent portfolio, U.S.-based manufacturing capabilities, and strategic industry relationships. The Company’s business includes proprietary biomaterials and medical device technologies, as well as contract manufacturing and other advanced ceramics opportunities. SINTX’s product portfolio includes the FDA-cleared SiNAPTIC® Foot & Ankle Osteotomy Wedge System for reconstructive surgery.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, among other things, statements regarding the Company’s expectations concerning its fourth-quarter 2026 revenue; anticipated operating results, including expectations regarding narrowed losses; the Company’s ability to achieve reliable delivery, repeat business and disciplined manufacturing costs; the continued development and commercialization of the Company’s silicon nitride technology platform and related applications; the Company’s transition toward a more diversified commercial-stage advanced materials company; the Company’s intention and ability to call the Class B Warrants; the potential exercise of such warrants by holders; and the amount and availability of any proceeds resulting from such exercises. The Company’s reported third-quarter 2026 revenue is preliminary and unaudited and remains subject to completion of the Company’s quarter-end financial close and review procedures. Final reported results may differ from the preliminary results described in this release, including as a result of adjustments identified during the closing and financial reporting process. Forward-looking statements are based on management’s current expectations, estimates and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include, among others, the Company’s ability to successfully develop and commercialize its products and technologies; obtain and maintain applicable regulatory clearances or approvals; achieve market acceptance among surgeons, healthcare providers, distributors and other customers; substantiate anticipated product characteristics and performance; protect and enforce its intellectual property; manufacture products at commercial scale; satisfy customer orders on expected schedules; maintain manufacturing throughput and operational efficiencies; manage manufacturing and operating costs; successfully execute its strategic and commercial objectives; and the risks associated with the Class B Warrants, including that holders may not exercise the warrants and that the Company may receive less proceeds than anticipated or no proceeds at all, as well as the risks and uncertainties described in the Company’s filings with the U.S. Securities and Exchange Commission, including under the heading “Risk Factors” in the Company’s most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q and other SEC filings. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date of this release. The Company undertakes no obligation to update any forward-looking statement, except as required by applicable law.
Company Contact:
Andrew Benson
SINTX Technologies, Inc.
801.839.3500
IR@sintx.com